Head And Neck Cancer
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Only a few studies have investigated the effectiveness of pazopanib and cetuximab, an angiogenesis inhibitor and EGFR inhibitor, respectively, for head and neck squamous cell carcinoma.
The anti-programmed death 1 (PD-1) antibody pembrolizumab was determined to be an effective second-line option for patients with head and neck cancers.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Motolimod Combination Therapy Does Not Improve Survival in Squamous Cell Carcinoma of the Head and NeckJune 27, 2018
Previous studies have demonstrated that motolimod can induce positive immune responses, but it did not improve outcomes in the first-line setting in squamous cell carcinoma of the head and neck in the featured study.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHNJune 03, 2018
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
When variables such as age and serious medical conditions were accounted for cancer versus non-cancer mortality was two times higher for women compared with men.
Immune-Related Adverse Events During Anti-PD-1 Therapy May Increase Survival in Head and Neck CancerJune 02, 2018
It is believed that immune competence may modify anti-tumor response with anti-PD-1 therapy.
Two year treatment with pembrolizumab prolonged overall survival compared with standard of care among patients with HNSCC, but the effects on quality of life require further elucidation.
Researchers sought to determine if the addition of nivolumab to radiotherapy and chemotherapy could improve outcomes among this patient population.
Although the addition of stereotactic body radiation therapy (SBRT) to nivolumab did not increase toxicity, it did not lead to any improvement in response rates or survival outcomes among patients with metastatic head and neck squamous cell carcinoma (HNSCC).
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
The CYCORE system may enable physicians to intervene at the early signs of dehydration and other radiotherapy-associated symptoms.
View detailed treatment regimens for head and neck cancers, with options such as cisplatin, cisplatin + radiotherapy, and more.
Oesophagogastro duodenoscopy is a diagnostic procedure to diagnose esophagogastric cancer, but is highly invasive and expensive.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
The total morphine equivalents used were, however, not significantly different between arms.
These findings were, however, significant only in states that expanded Medicaid eligibility.
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
The number of PCA attempts did not differ between treatment arms.
Approximately 50% and 30% of patients with late- and early-stage disease, respectively, undergo surgery without adjuvant therapy.
The mean total opioid morphine equivalent use in the celecoxib arm was 31.8 mg vs 45 mg in the control arm.
The benefit of adjuvant radiotherapy in this setting was previously unestablished.
Check-Mate 141 Results: Nivolumab Improved OS in Patients With Recurrent or Metastatic Head and Neck CancerApril 18, 2018
Not all patients who received nivolumab, however, had improved PFS.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer